OptimizeRx Q2 revenue up 3% to $14M; GAAP net loss $3.9M, cuts FY2022 guidance

OptimizeRx Corp

2022-Q2 EPS reported -$0.42 revenue$27,710,195

Revenue $14.0M (+3% YoY); gross margin improved to 64% from 59%.
GAAP net loss $3.9M ($0.21 loss per share) vs net income $0.4M in Q2 2021.
Non-GAAP net loss $0.7M ($0.04 loss per share) vs $1.8M income year ago.
Updated FY2022 revenue outlook to $62-68M (1-11% growth), citing temporary industry headwinds.
Closed EvinceMed acquisition in April; repurchased 232,745 shares under $20M buyback program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.